600380 健康元
午间休市 09-09 11:29:53
资讯
新帖
简况
股市必读：健康元（600380）9月8日董秘有最新回复
证券之星 · 01:01
股市必读：健康元（600380）9月8日董秘有最新回复
健康元：公司现有多款治疗哮喘的吸入制剂
证券之星 · 09-07 17:27
健康元：公司现有多款治疗哮喘的吸入制剂
健康元：公司目前暂无专门针对鼻病毒的特效抗病毒药物
证券之星 · 09-07 17:27
健康元：公司目前暂无专门针对鼻病毒的特效抗病毒药物
健康元：BD合作引进与自主研发并行
证券之星 · 09-07 17:27
健康元：BD合作引进与自主研发并行
健康元：公司当前销售费用率处于行业合理水平
证券之星 · 09-07 17:27
健康元：公司当前销售费用率处于行业合理水平
健康元：全力推进产品上量
证券之星 · 09-07 17:27
健康元：全力推进产品上量
健康元：持有ω-3鱼油中/长链脂肪乳注射液注册批件
证券之星 · 09-07 17:27
健康元：持有ω-3鱼油中/长链脂肪乳注射液注册批件
健康元：公司将结合整体产业战略、资金分配规划及各项合规要求综合研判、审慎决策各种方案
证券之星 · 09-07 17:27
健康元：公司将结合整体产业战略、资金分配规划及各项合规要求综合研判、审慎决策各种方案
子公司收购的越南IMP医药公司，是否养实验猴？健康元回应
同花顺 · 09-07 17:13
子公司收购的越南IMP医药公司，是否养实验猴？健康元回应
健康元：公司目前暂无变更公司名称或证券简称的相关计划与安排
证券之星 · 09-07 17:12
健康元：公司目前暂无变更公司名称或证券简称的相关计划与安排
健康元：公司暂时目前没有专门针对新冠病毒的特效治疗药物
证券之星 · 09-07 17:12
健康元：公司暂时目前没有专门针对新冠病毒的特效治疗药物
健康元：目前公司暂无自主主导开发、处于临床阶段的 CGT 在研管线
证券之星 · 09-07 17:12
健康元：目前公司暂无自主主导开发、处于临床阶段的 CGT 在研管线
健康元：目前暂未开展mRNA方向的AI靶点筛选相关项目
证券之星 · 09-07 17:03
健康元：目前暂未开展mRNA方向的AI靶点筛选相关项目
健康元：关于玛帕西沙韦医保准入工作
证券之星 · 09-07 17:03
健康元：关于玛帕西沙韦医保准入工作
股市必读：健康元新发布《健康元药业集团股份有限公司关于获得《药品注册证书》的公告》
证券之星 · 08-31
股市必读：健康元新发布《健康元药业集团股份有限公司关于获得《药品注册证书》的公告》
每周股票复盘：健康元（600380）Q2净利降33.36%
证券之星 · 08-30
每周股票复盘：健康元（600380）Q2净利降33.36%
健康元（600380）披露获得《药品注册证书》公告，8月28日股价上涨0.97%
证券之星 · 08-28
健康元（600380）披露获得《药品注册证书》公告，8月28日股价上涨0.97%
股市必读：健康元中报 - 第二季度单季净利润同比下降33.36%
证券之星 · 08-26
股市必读：健康元中报 - 第二季度单季净利润同比下降33.36%
健康元（600380）披露2026年半年度报告，8月25日股价下跌1.18%
证券之星 · 08-25
健康元（600380）披露2026年半年度报告，8月25日股价下跌1.18%
图解健康元中报：第二季度单季净利润同比下降33.36%
证券之星 · 08-25
图解健康元中报：第二季度单季净利润同比下降33.36%
加载更多
公司概况
公司名称：
健康元药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2001-06-08
主营业务：
健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品。
发行价格：
24.80
{"stockData":{"symbol":"600380","market":"SH","secType":"STK","nameCN":"健康元","latestPrice":9.46,"timestamp":1788924593000,"preClose":9.57,"halted":0,"volume":7563098,"delay":0,"changeRate":-0.0115,"floatShares":1829000000,"shares":1829000000,"eps":0.655,"marketStatus":"午间休市","change":-0.11,"latestTime":"09-09 11:29:53","open":9.51,"high":9.54,"low":9.44,"amount":71705300,"amplitude":0.0104,"askPrice":9.47,"askSize":223,"bidPrice":9.46,"bidSize":289,"shortable":0,"etf":0,"ttmEps":0.655,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788930000000},"marketStatusCode":3,"adr":0,"adjPreClose":9.57,"symbolType":"stock","openAndCloseTimeList":[[1788917400000,1788924600000],[1788930000000,1788937200000]],"highLimit":10.53,"lowLimit":8.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1829453386,"isCdr":false,"pbRate":1.15,"roa":"--","peRate":14.442748,"roe":"4.21%","epsLYR":0.73,"committee":0.535771,"marketValue":17307000000,"turnoverRate":0.0041,"status":1,"floatMarketCap":17307000000},"requestUrl":"/m/hq/s/600380","defaultTab":"news","newsList":[{"id":"2666374466","title":"股市必读：健康元（600380）9月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374466?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:01","pubTimestamp":1788886885,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，健康元报收于9.57元，上涨0.31%，换手率1.05%，成交量19.27万手，成交额1.84亿元。公司 AI 制药与合成生物学赛道积极布局，持续推进技术研发并取得阶段性成果。AI 药物研发方面，公司搭建医药智能研发平台，覆盖靶点挖掘、分子设计、处方筛选、临床方案设计等新药研发全链条，可有效压缩创新药早期研发周期，降低研发试错投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0114","BK0239","BK0028","BK0188","BK0077","600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319777","title":"健康元：公司现有多款治疗哮喘的吸入制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319777?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:27","pubTimestamp":1788773236,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元(600380)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：近期，各地强对流天气不断，造成雷暴雨极端气候，很多医院因我雷暴哮喘人满为患，强雷暴空气中的花粉和孢子到处飘散，贵公司有没有针对性药物？健康元回复：尊敬的投资者，您好，雷雨天气花粉、孢子扩散引发的雷暴哮喘，多表现为哮喘急性发作。公司现有多款治疗哮喘的吸入制剂，能够对症缓解气道痉挛，满足临床救治需求。但该类药品均为处方药，注意需在专业医师指导下合理使用。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0188","BK0046","600380","BK0114","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831977","title":"健康元：公司目前暂无专门针对鼻病毒的特效抗病毒药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665831977?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:27","pubTimestamp":1788773234,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元(600380)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：近期鼻病毒显著高发，健康元有没有针对性药物？健康元回复：尊敬的投资者，您好。公司目前暂无专门针对鼻病毒的特效抗病毒药物。鼻病毒感染多引发上呼吸道炎症，容易诱发咳嗽、喘息甚至哮喘急性发作。公司拥有较为完善的呼吸类对症药物，布地奈德、特布他林等吸入制剂，可有效缓解气道炎症与痉挛，改善鼻病毒感染继发的呼吸道症状。但该类药品均为处方药，注意需在专业医师指导下合理使用。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0046","BK0028","BK0114","600380","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665197053","title":"健康元：BD合作引进与自主研发并行","url":"https://stock-news.laohu8.com/highlight/detail?id=2665197053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665197053?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:27","pubTimestamp":1788773234,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元09月07日在投资者关系平台上答复投资者关心的问题。在通过BD合作快速搭建创新管线的同时，公司也在持续推进自主研发布局，稳步夯实自研创新能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0239","BK0028","BK0046","600380","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319720","title":"健康元：公司当前销售费用率处于行业合理水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319720?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:27","pubTimestamp":1788773233,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元09月07日在投资者关系平台上答复投资者关心的问题。同时通过数字化运营、全渠道布局优化，持续提升费用投放精准度与转化效率，稳固销售费用合理可控的状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","600380","BK0188","BK0077","BK0239","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319703","title":"健康元：全力推进产品上量","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319703?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:27","pubTimestamp":1788773233,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元09月07日在投资者关系平台上答复投资者关心的问题。当前公司首要工作是全力推进产品上量，通过常态化全国学术交流，向医院科室充分传递产品循证疗效，稳步拓展各级医院准入覆盖，同步做好患者科普宣教，提升医患对规范足疗程治疗的认知，同时优化渠道配送保障院内稳定供货，多措并举逐步提升产品市场普及率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600380","BK0114","BK0077","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319773","title":"健康元：持有ω-3鱼油中/长链脂肪乳注射液注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319773","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319773?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:27","pubTimestamp":1788773232,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元(600380)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：国家要求发展海洋生物医药，AI大模型表示健康元涉足，能否披露下健康元涉足哪些海洋生物药？健康元回复：尊敬的投资者，您好，公司持有ω-3鱼油中/长链脂肪乳注射液的注册批件，该产品属于海洋来源的制剂，但是暂未形成重大销售，谢谢。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600380","BK0028","BK0114","BK0046","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319708","title":"健康元：公司将结合整体产业战略、资金分配规划及各项合规要求综合研判、审慎决策各种方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319708?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:27","pubTimestamp":1788773224,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元(600380)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价已经处于及时低位估值水平，建议通过增持丽珠集团股票方式，可以同时提振丽珠集团和健康元估价，关键是提高持股比例，增厚归属母公司利润健康元回复：尊敬的投资者，您好，感谢您的宝贵建议。公司将结合整体产业战略、资金分配规划及各项合规要求综合研判、审慎决策各种方案。现阶段资金资源也需优先保障两家企业创新研发、国际化布局等长期发展投入。若后续推出相关安排，公司会严格依照信息披露相关规定，第一时间对外公告。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0114","600380","BK0239","BK0046","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313375","title":"子公司收购的越南IMP医药公司，是否养实验猴？健康元回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313375","media":"同花顺","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665313375?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:13","pubTimestamp":1788772380,"startTime":"0","endTime":"0","summary":"有投资者向健康元(600380.SH)提问，健康元子公司收购的越南IMP医药公司，是不是有养实验猴？9月7日，公司回答表示，越南IMP公司是越南本土上市制药企业，主营业务为化学制剂的研发、生产与 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260907/c679661641.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260907/c679661641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","600380","BK0028","BK0114","BK0046","BK0188","FVNmain","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319680","title":"健康元：公司目前暂无变更公司名称或证券简称的相关计划与安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319680?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:12","pubTimestamp":1788772330,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元(600380)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问上市公司，有没有打算更名，比如健康科技？健康元回复：尊敬的投资者，您好。感谢您的建议，公司目前暂无变更公司名称或证券简称的相关计划与安排。若未来涉及更名事项，公司将严格履行法定的审议程序以及交易所信息披露义务，所有相关事项请以公司正式公告为准。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","600380","BK0077","161027","BK0188","BK0028","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319597","title":"健康元：公司暂时目前没有专门针对新冠病毒的特效治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319597","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319597?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:12","pubTimestamp":1788772330,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元(600380)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：近期新冠病毒又有上升趋势，贵公司有什么特效药可以抵抗病毒健康元回复：尊敬的投资者，您好。公司暂时目前没有专门针对新冠病毒的特效治疗药物。但在流感季节、对于新冠感染引发的相关呼吸道症状，公司拥有多款吸入制剂产品，可用于缓解新冠带来的呼吸道相关病症。后续公司也会持续关注市场变化，做好相关产品的生产供应保障。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","BK0028","BK0239","BK0188","600380","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319564","title":"健康元：目前公司暂无自主主导开发、处于临床阶段的 CGT 在研管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319564?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:12","pubTimestamp":1788772329,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元(600380)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：CGT药品临床通道30天，健康元有没有布局健康元回复：尊敬的投资者，您好。目前公司暂无自主主导开发、处于临床阶段的 CGT 在研管线。未来，公司将持续跟踪行业政策与技术迭代，结合自身情况审慎评估 CGT 领域的研发与合作机会，谢谢。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0028","BK0239","600380","BK0114","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319686","title":"健康元：目前暂未开展mRNA方向的AI靶点筛选相关项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319686?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:03","pubTimestamp":1788771793,"startTime":"0","endTime":"0","summary":"未来子公司疫苗，会不会从重组蛋白转换到mRNA方向？AI 技术在靶点筛选、分子设计等生物医药领域拥有广阔应用前景，公司会持续跟踪 AI 制药的技术发展趋势，但目前暂未开展 mRNA 方向的 AI 靶点筛选相关项目。子公司疫苗业务当前主要布局重组蛋白技术路线，mRNA 为完全不同的技术平台，后续公司将结合自身技术储备、资源条件审慎评估相关合作与布局机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0028","BK0077","600380","BK0114","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319637","title":"健康元：关于玛帕西沙韦医保准入工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319637?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:03","pubTimestamp":1788771790,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元09月07日在投资者关系平台上答复投资者关心的问题。当前获批 2 粒 / 盒为经过临床试验及药监审评确认的法定上市包装规格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0077","BK0239","600380","BK0046","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663042762","title":"股市必读：健康元新发布《健康元药业集团股份有限公司关于获得《药品注册证书》的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663042762","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663042762?lang=zh_cn&edition=full","pubTime":"2026-08-31 03:14","pubTimestamp":1788117251,"startTime":"0","endTime":"0","summary":"公司公告汇总健康元药业集团股份有限公司关于获得《药品注册证书》的公告健康元药业集团股份有限公司控股子公司丽珠单抗收到国家药监局核准签发的《药品注册证书》，其研发的莱康奇塔单抗注射液获批上市，药品批准文号为国药准字S20260065，有效期至2031年8月24日。该药品为国内首个自主研发的IL-17A/F双靶点创新生物制剂，适应症为中重度斑块状银屑病成人患者。截至公告日，累计研发投入约22,331万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100000918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0077","BK0114","BK0046","BK0239","600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663701090","title":"每周股票复盘：健康元（600380）Q2净利降33.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701090","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663701090?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:02","pubTimestamp":1788030137,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，健康元报收于9.37元，较上周的9.88元下跌5.16%。股本股东变化截至2026年6月30日，健康元股东户数为7.49万户，较3月31日减少1120户，减幅1.47%。业绩披露要点健康元2026年中报显示，上半年主营收入65.83亿元，同比下降16.66%；归母净利润6.48亿元，同比下降17.49%；扣非净利润6.04亿元，同比下降21.55%。第二季度单季营收28.61亿元，同比下降24.88%；单季归母净利润2.33亿元，同比下降33.36%；单季扣非净利润1.98亿元，同比下降42.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000000990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0046","BK0114","600380","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662699910","title":"健康元（600380）披露获得《药品注册证书》公告，8月28日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662699910","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662699910?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:01","pubTimestamp":1787911312,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，健康元报收于9.37元，较前一交易日上涨0.97%，最新总市值为171.42亿元。健康元药业集团股份有限公司于近日披露《关于获得〈药品注册证书〉的公告》。公告显示，公司控股子公司丽珠单抗收到国家药监局核准签发的《药品注册证书》，其研发的莱康奇塔单抗注射液获批上市，药品批准文号为国药准字S20260065，有效期至2031年8月24日。截至公告日，累计研发投入约22,331万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800042182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0046","BK0114","600380","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662579427","title":"股市必读：健康元中报 - 第二季度单季净利润同比下降33.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662579427","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662579427?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:34","pubTimestamp":1787693655,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年中报显示主营收入65.83亿元、归母净利润6.48亿元，同比分别下降16.66%和17.49%；第二季度单季归母净利润同比下降33.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600008531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736193","title":"健康元（600380）披露2026年半年度报告，8月25日股价下跌1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736193","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736193?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655475,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，健康元报收于9.24元，较前一交易日下跌1.18%，最新总市值为169.04亿元。该股当日开盘9.28元，最高9.38元，最低9.16元，成交额达2.1亿元，换手率为1.25%。健康元药业集团股份有限公司于近日披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为34,715,790,522.32元，较上年度末下降1.97%；归属于上市公司股东的净资产为15,221,206,583.02元，较上年度末增长0.27%。经营活动产生的现金流量净额为2,042,478,501.51元，同比增长6.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0114","BK0028","BK0239","BK0077","600380","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662520351","title":"图解健康元中报：第二季度单季净利润同比下降33.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662520351","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662520351?lang=zh_cn&edition=full","pubTime":"2026-08-25 02:05","pubTimestamp":1787594751,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元2026年中报显示，上半年度公司主营收入65.83亿元，同比下降16.66%；归母净利润6.48亿元，同比下降17.49%；扣非净利润6.04亿元，同比下降21.55%；其中2026年第二季度，公司单季度主营收入28.61亿元，同比下降24.88%；单季度归母净利润2.33亿元，同比下降33.36%；单季度扣非净利润1.98亿元，同比下降42.82%；负债率31.57%，投资收益1.16亿元，财务费用-742.45万元，毛利率58.7%。财报数据概要请见下图:本文数据来源于健康元2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500005163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788926314194,"stockEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":-0.0673},{"period":"3month","weight":-0.0053},{"period":"6month","weight":-0.1291},{"period":"1year","weight":-0.2701},{"period":"ytd","weight":-0.1526}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.0457},{"period":"1year","weight":0.0297},{"period":"ytd","weight":-0.0071}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"健康元药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"74898人(较上一季度减少1.47%)","perCapita":"24425股","listingDate":"2001-06-08","address":"广东省深圳市南山区高新区北区朗山路17号健康元药业集团大厦","registeredCapital":"182945万元","survey":" 健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品。","listedPrice":24.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健康元,600380,健康元股票,健康元股票老虎,健康元股票老虎国际,健康元行情,健康元股票行情,健康元股价,健康元股市,健康元股票价格,健康元股票交易,健康元股票购买,健康元股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}